Condition (MeSH)
Polychondritis, Relapsing
ClinicalTrials.gov lists 11 trials for Polychondritis, Relapsing or a narrower condition beneath it. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
11 of the 11 trials are tagged with Polychondritis, Relapsing itself; the rest are tagged with a narrower condition beneath it.
When did Polychondritis, Relapsing trials start? (9)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 1 |
| 2021 | 2 |
| 2019 | 1 |
| 2015 | 1 |
| 2014 | 1 |
| 2011 | 1 |
| 2010 | 2 |
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Polychondritis, Relapsing trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 2 | 4 |
| Not applicable | 1 |
| Observational | 4 |
How many Polychondritis, Relapsing trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 4 |
| Completed | 3 |
| Terminated | 1 |
| Withdrawn | 1 |
| Unknown status | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Polychondritis, Relapsing trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 1 |
Which drugs are being tested for Polychondritis, Relapsing? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| INFLIXIMAB | 2 |
| RITUXIMAB | 1 |
| IL2 | 1 |
Interventions as named in the registry (7)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| tocilizumab SC | 4 |
| corticosteroids and immunosuppressants | 1 |
| Adalimumab-US | 1 |
| Azathioprine Pill | 1 |
| Abatacept SC | 1 |
Showing 5 of 7 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Polychondritis, Relapsing trials report? (8)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Cellulitis | 1 | 1 |
| Myocardial infarction | 1 | 1 |
| Oral candidiasis | 1 | 1 |
| Polychondritis | 1 | 1 |
| Septic shock | 1 | 1 |
Showing 5 of 8 adverse events.
Which publications cover Polychondritis, Relapsing? (8)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Physician Global Assessment as a Disease Activity Measure for Relapsing Polychondritis. | Arthritis care & research | 2022 | Yes |
| Abatacept in relapsing polychondritis. | Annals of the rheumatic diseases | 2013 | Yes |
| Sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis. | Rheumatology (Oxford, England) | 2009 | Yes |
| Serum cytokine profiles in relapsing polychondritis suggest monocyte/macrophage activation. | Arthritis and rheumatism | 2004 | Yes |
| Treatment of diffuse tracheomalacia secondary to relapsing polychondritis with continuous positive airway pressure. | Chest | 1997 | Yes |
Showing 5 of 8 publications.
Prevalence (15)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Relapsing polychondritis | Point prevalence | 1-9 / 1 000 000 | United Kingdom | GB | Exact |
| Relapsing polychondritis | Point prevalence | 1-9 / 1 000 000 | United Kingdom | GB | Exact |
| Relapsing polychondritis | Annual incidence | <1 / 1 000 000 | United Kingdom | GB | Exact |
| Relapsing polychondritis | Annual incidence | <1 / 1 000 000 | United Kingdom | GB | Exact |
| Relapsing polychondritis | Annual incidence | <1 / 1 000 000 | United Kingdom | GB | Unspecified |
Showing 5 of 15 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Relapsing polychondritis | 728 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Relapsing polychondritis | 728 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.